PAVmed Inc.·3

Apr 6, 9:46 PM ET

Tasso Partners, LLC 3

3 · PAVmed Inc. · Filed Apr 6, 2026

Insider Transaction Report

Form 3
Period: 2026-03-27
Holdings
  • Common Stock

    912,996
  • Warrants

    [F1]
    Exercise: $1000.00From: 2026-02-03Exp: 2031-02-03Series D Preferred Stock (5,365 underlying)
Footnotes (1)
  • [F1]The Warrant entitles the reporting person to purchase up to 5,365 shares of Series D Preferred Stock at an exercise price of $1,000 per share. Each share of Series D Preferred Stock has a stated value of $1,000 per share and is convertible into shares of Common Stock at a conversion price of $6.50 per share, for an aggregate of up to 825,385 shares of Common Stock. Upon exercise of the Warrant, the Issuer may, in lieu of issuing the Series D Preferred Stock, issue to the reporting person the number of shares of Common Stock that would be issuable to the holder upon conversion of the Series D Preferred Stock.
Signature
/s/ Dana Carrera, as manager of managing member|2026-04-06

Documents

1 file
  • 3
    form3.xmlPrimary

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES